BOEU.F Stock Overview
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 32.28 |
| 52 Week High | SEK 33.50 |
| 52 Week Low | SEK 18.60 |
| Beta | 0.97 |
| 11 Month Change | 0.88% |
| 3 Month Change | n/a |
| 1 Year Change | 105.09% |
| 33 Year Change | 672.42% |
| 5 Year Change | n/a |
| Change since IPO | 493.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOEU.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.2% | -3.7% | 0.3% |
| 1Y | 105.1% | 15.2% | 31.1% |
Return vs Industry: BOEU.F exceeded the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: BOEU.F exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| BOEU.F volatility | |
|---|---|
| BOEU.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BOEU.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BOEU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 131 | Emil Billbäck | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| BOEU.F fundamental statistics | |
|---|---|
| Market cap | US$2.15b |
| Earnings (TTM) | US$8.20m |
| Revenue (TTM) | US$73.75m |
261.5x
P/E Ratio29.1x
P/S RatioIs BOEU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOEU.F income statement (TTM) | |
|---|---|
| Revenue | SEK 814.46m |
| Cost of Revenue | SEK 61.64m |
| Gross Profit | SEK 752.82m |
| Other Expenses | SEK 662.24m |
| Earnings | SEK 90.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 1.38 |
| Gross Margin | 92.43% |
| Net Profit Margin | 11.12% |
| Debt/Equity Ratio | 0% |
How did BOEU.F perform over the long term?
See historical performance and comparison